Downgrade Alert for BioCryst Pharmaceuticals (BCRX)
BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded from Neutral to Underperform at BofA/Merrill today. The stock closed yesterday at $10.21 on volume of 564,000 shares, below average daily volume of 1.1 million.
BioCryst Pharmaceuticals, Inc., a biopharmaceutical company, discovers and designs novel small-molecule pharmaceuticals using structure-based drug design. The Company's products are used for the treatment of immunological, viral, and cardiovascular diseases and disorders. BioCryst's lead immunological drug program targets T-cell proliferative disorders.
In the past 52 weeks, BioCryst Pharmaceuticals share prices have been bracketed by a low of $7.85 and a high of $16.83 and closed yesterday at $10.21, 30% above that low price. In the last five trading sessions, the 50-day moving average (MA) has fallen 0.9% while the 200-day MA has slid 0.2%.
BioCryst Pharmaceuticals has overhead space with shares priced $10.21, or 45.9% below the average consensus analyst price target of $18.86. BioCryst Pharmaceuticals shares should first meet resistance at the 50-day moving average (MA) of $10.73 and find additional resistance at the 200-day MA of $11.43.
SmarTrend recommended that its subscribers protect gains by selling shares of BioCryst Pharmaceuticals on September 28th, 2015 by issuing a Downtrend alert when the shares were trading at $10.96. Since that call, shares of BioCryst Pharmaceuticals have fallen 6.8%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time.
Keywords: analyst upgrades/downgrades biocryst pharmaceuticals